Biotech Values

[ghmm]

I don't think it is a big risk for BMRN as well. I was actually more surprised that RNA would sell rather then seek another license. You do bring up a good point about the trial for another Exon. I am fairly certain of EU approval and the way SRPT has moved in the EU BMRN's lead there even if IP is settled is much greater. I will be watching PTC closely to see how reimbursement goes though.

I certainly don't have the legal background but can't get to seeing it being a huge royalty to license the IP given the differences in technology (I thought single digits).

For the record I never worried about the AE profile from an approval standpoint only from a standpoint if both drugs were available in the same market. I am in the camp that actually thought/thinks both RNA and SRPT drugs get approved (picking them both in the SI charity portfolio). My only mistake was trying to get a cheaper entry for RNA in real life from an already pretty low valuation post GSK :(.